Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Epstein-Barr Viral Infections Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Epstein-Barr Viral Infections Overview | 10 | 1 |
| Pipeline Products for Epstein-Barr Viral Infections Comparative Analysis | 11 | 1 |
| Epstein-Barr Viral Infections Therapeutics under Development by Companies | 12 | 1 |
| Epstein-Barr Viral Infections Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Epstein-Barr Viral Infections Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Epstein-Barr Viral Infections Products under Development by Companies | 17 | 1 |
| Epstein-Barr Viral Infections Products under Investigation by Universities/Institutes | 18 | 1 |
| Epstein-Barr Viral Infections Companies Involved in Therapeutics Development | 19 | 11 |
| Arno Therapeutics, Inc. | 19 | 1 |
| Cell Medica Limited | 20 | 1 |
| Epiphany Biosciences, Inc. | 21 | 1 |
| Genocea Biosciences, Inc. | 22 | 1 |
| Humabs BioMed SA | 23 | 1 |
| Molplex Ltd. | 24 | 1 |
| Omeros Corporation | 25 | 1 |
| Savoy Pharmaceuticals, Inc. | 26 | 1 |
| Theravectys SA | 27 | 1 |
| Vironika, LLC | 28 | 1 |
| ViroStatics srl | 29 | 1 |
| Epstein-Barr Viral Infections Therapeutics Assessment | 30 | 9 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Target | 31 | 2 |
| Assessment by Mechanism of Action | 33 | 2 |
| Assessment by Route of Administration | 35 | 2 |
| Assessment by Molecule Type | 37 | 2 |
| Drug Profiles | 39 | 29 |
| AR-12 Drug Profile | 39 | 3 |
| Cellular Immunotherapy for EBV Associated PTLD Drug Profile | 42 | 1 |
| Cellular Immunotherapy for Infectious Disease Drug Profile | 43 | 1 |
| Cellular Immunotherapy for Infectious Diseases Drug Profile | 44 | 1 |
| Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections Drug Profile | 45 | 1 |
| Cellular Immunotherapy for Viral Infections Drug Profile | 46 | 1 |
| Cellular Immunotherapy for Viral Infections Post-HSCT Drug Profile | 47 | 1 |
| Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma Drug Profile | 48 | 1 |
| Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection Drug Profile | 49 | 1 |
| Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases Drug Profile | 50 | 1 |
| Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile | 51 | 1 |
| CMD-003 Drug Profile | 52 | 2 |
| Epstein-Barr virus (virus like particle) vaccine Drug Profile | 54 | 1 |
| Epstein-Barr virus vaccine Drug Profile | 55 | 1 |
| Monoclonal Antibody for Epstein-Barr Viral Infection Drug Profile | 56 | 1 |
| MVA vaccine Drug Profile | 57 | 1 |
| Small Molecule for Infectious Mononucleosis Drug Profile | 58 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile | 59 | 1 |
| Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections Drug Profile | 60 | 2 |
| Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections Drug Profile | 62 | 1 |
| Small Molecules to Inhibit EBNA1 for Epstein-Barr Viral Infections Drug Profile | 63 | 1 |
| Vaccine for Epstein-Barr Virus and Oncology Drug Profile | 64 | 1 |
| valomaciclovir stearate Drug Profile | 65 | 2 |
| Viroprev Drug Profile | 67 | 1 |
| Epstein-Barr Viral Infections Dormant Projects | 68 | 1 |
| Epstein-Barr Viral Infections Product Development Milestones | 69 | 1 |
| Featured News &Press Releases | 69 | 1 |
| Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus | 69 | 1 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |